Eric Belair

Securing funding to expand CMHA programs, funding for mental health and mental health research Development of national standards for access to mental health services. Arranging meetings and outreach with public office holders to discuss mental health and addictions policy, service delivery, and programs.

Seeking repayable and non-repayable funding to support of Crawford Nickel-Cobalt Sulphide Project as well as downstream elements to support the EV Battery supply chain.

Seeking funding to support of Crawford Nickel-Cobalt Sulphide Project as well as downstream elements to support the EV Battery supply chain.

Engaging with the federal government on policies and funding opportunities pertaining to project approval and advancement for the Crawford Nickel-Cobalt Sulphide discovery and downstream elements, including northern Ontario economic development policy, the competitiveness of the mining sector, mine development, downstream processing, permitting, and environmental policy.

Regulations, policies and programs related to the reimbursement recommendations decision-making process and framework done by the Canadian Agency for Drugs and Technologies in Health (CADTH)/Common Drug Review as well as the review times and processes conducted by Health Canada for the purpose of obtaining a notice of compliance. National Strategy for Drugs for Rare Disease as it relates to separate regulatory pathways for drugs for rare diseases and the government strategy. Monitoring and engaging the Government and Parliamentarians on policies and programs that would provide greater clarity and predictability in the tax outcomes and improvements to tax measures such as the Manufacturing & Processing (M&P) credit and the Scientific Research & Developmental (SR&ED). Common Drug Review Policies as it relates to reimbursement recommendation decision-making process and framework. Federal Public Drug Plans, with respect to the reimbursement of therapeutic products for Federal plan beneficiaries Policies related to the National Strategy for Drugs for Rare Disease as it relates to separate regulatory pathway for drugs for rare diseases and the government strategy. Policies related to Subsequent Entry Biologics (SEBs) pertaining to Draft Guidance for Sponsors; Information and Submission requirements for SEBs, regulations and intellectual property policies, naming conventions Monitoring and engaging on the Government’s commitment (Budget, SFT, Fall Economic Update) to create a national strategy for drugs for rare diseases; create a new Canadian Drug Agency; and the implementation of national, universal pharmacare. Pharmaceutical policy and any negotiations of a Health Accord or agreement with the Provinces/Territories, as it relates to National Pharmacare/universal or catastrophic drug coverage, Drug policies & Pricing. The Department of Innovation, Science and Economic Development and the Innovation Agenda for the life sciences sector: policy or program initiatives to support life science research and development conducted in Canada and manufacturing capability, and as it relates to Canada’s Biomanufacturing and Life Sciences Strategy. Monitoring and engaging the Government and Parliamentarians on policies and programs related to Canada's biomanufacturing and life sciences sector strategy National Pharmacare (Bill C-64, An Act respecting pharmacare) Canadian Environmental Protection Act and Regulations in respect of modern, science-based regulations to reflect rapidly changing new technologies. Patent Act as it relates to reporting requirements and pricing guidelines, and the protection of intellectual property in biopharmaceutical products. Income Tax Act as it relates to biopharmaceutical industry. Annual federal Budgets and Budget updates as it relates to the biopharmaceutical industry, and related updates and to Federal budgetary policy. Discussions around the World Trade Organization consideration of a TRIPS Patent Waiver - Agreement on Trade-Related Aspects of Intellectual Property Rights (TRIPs) with respect to the protection of data, Access to Medicines, and TRIPs "flexibility". The Food and Drugs Act, or the Export and Imports Permits Act (Export Control List) or any other legislative and regulatory means in order to protect the Canadian supply of drugs in light of importation legislation in the United States. Standing Committee on Finance (FINA) as it relates to pre-budget consultations. Pharmaceutical intellectual property protection as it relates to international trade agreements Patent Act and Patented Medicines (Notice of Compliance) Regulations, as it relates to the regulation of intellectual property, approval for therapeutic products, changes to modernize the Right of Appeal House of Commons Standing Committee of Science and Research (SRSR) as it relates to Science in Canada and/or any other pertinent legislative proposal before the committee House of Commons Standing Committee of Industry and Technology (INDU) as it

Communications regarding funding from various Government funding programs, opportunities to improve government activity (funding, tax incentives, clinical trials infrastructure, etc) to encourage the innovation economy in Canada with a specific focus on biotech, and programs around procurement opportunities for the Government of Canada relating to biotechnology products.

The pan Canadian Pharmaceutical Alliance (pCPA) with respect to public formulary listing of new medicines, insofar as the federal government is a participating jurisdiction and holds a seat on the Board of Directors. Public Health Agency of Canada, regarding the federal response to the hepatitis C virus. Patented Medicine Prices Review Board (PMPRB) Guidelines with regard to prices charged by Rights Holders for patented medicines sold in Canada. Innovation, Science and Economic Development (ISED)'s Biomanufacturing and Life Sciences Strategy, pertaining to growth and development of the life sciences industry in Canada. Federal Government Non Insured Health Benefits program with respect to reimbursement of a prescription medicine and changes in type of reimbursement Engagement with Health Canada’s Regulatory Operations & Enforcement branch regarding supply chain resilience & integrity; mitigating and alleviating drug shortages. Communications with Heath Canada regarding modernization of the medical devices regulatory framework. Communications with Health Canada regarding the evolution of the regulatory framework to address advanced therapeutic products. Communications with Health Canada regarding the application of its nitrosamine guidelines. Communications with Health Canada regarding modernization of clinical trials regulations, including diversity and inclusivity of clinical trials. Communications with Health Canada regarding guidelines for pediatric action plans. Communications regarding the value assessment of new medicines by the Canadian Drug Agency (CDA) and the design of proposed new work streams, insofar as the federal government is a funder and holds a seat on the Board of Directors. Communications regarding the design and implementation of the federal Drugs for Rare Diseases strategy. Communications regarding national pharmacare legislation, regulations, policies or programs. Communications regarding intellectual property protection of prescription drugs, including the Patent Act, the Patented Medicines Regulations, the Patented Medicine Notice of Compliance (PMNOC) Regulations, the Patent Term Adjustment regime and Health Canada’s Data Protection regime. Communications regarding Health Canada's Regulatory Innovation Agenda regarding proposed regulatory amendments and guidelines to enable agile licensing of drugs and medical devices. Communications regarding access to and approval of medicines addressing the growing public health threat of antimicrobial resistance.

Discussion with government officials on trade policy and priorities including items controlled for import and export in Canada

Communicated the need to secure infrastructure funding for Werklund Centre Transformation (WCT) initiative. Communicated the need for federal support of high-speed rail development between Edmonton and Calgary to enhance regional connectivity and improve transportation efficiency within Alberta. In regards to Canada's electricity framework, communicated that Alberta’s electricity sector is distinct within Canada, operating as a private and deregulated market that relies on attracting sustained capital investment. Communicated that this unique structure should be appropriately considered in the development of new federal regulatory frameworks. Discussed the importance of a unified cross-Canada approach to supporting Alberta’s long term economic competitiveness and investment climate. Emphasized the need for a cooperative federalism approach that delivers predictable policy, strengthens collaboration, and demonstrates that provincial-federal cooperation can effectively respond to regional economic priorities. General communication with the government regarding defense procurement opportunities for small and medium-sized enterprises. Communication with the government to discuss trade diversification generally, including free trade agreements, Canada-United-States-Mexico Agreement, and opportunities for growth in international markets. Communicating with the government regarding the development of trade-enabling infrastructure to facilitate inter-provincial and international trade Communicating with the government regarding the industrial carbon pricing framework. Communicating with the government regarding the impacts of the Climate Competitiveness Strategy 5. General communication on housing initiatives and agency coordination. 3. Engaging with the federal government on the proposed Regulatory Framework for an Oil and Gas Sector Greenhouse Gas Emissions Cap within the context of the Alberta-Canada MOU, emphasizing the need for a coordinated approach that supports emissions reduction while maintaining national economic competitiveness and investment in Alberta’s energy sector. 1. General communication on the Alberta-Canada MOU as an important step towards unlocking investment and strengthening long term growth in Canada General communication regarding impact to Canadian businesses as a result of international and national trade and trade barriers, including tariffs. General communication with government regarding talent, labour and workforce development to support Canadian businesses. General communication with government regarding international and interprovincial trade challenges or opportunities facing Canadian businesses. General communication with government regarding the importance of fiscal prudence, red tape reduction and competitiveness. Communication with the federal government regarding issues of safety and crime, in particular around prevention to support businesses in Canada. General communication regarding affordability concern for Canadian businesses. General communication with the Federal Government inquiring about opportunities to support Calgary Chamber of Commerce programming to support businesses, particularly small business. General communication with respect to initiatives and policies that impact Calgary's business community, both positively and negatively, relative to other jurisdictions. General communication with respect to climate and decarbonization policies and Canada's competitiveness relative to other jurisdictions. Communicating with the government regarding the feasibility and impacts of the proposed "Regulatory Framework for an Oil and Gas Sector Greenhouse Gas Emissions Cap". Specifically, communication detailed that the proposed emissions cap would negatively impact economic sectors across Canada. Communicating with the government regarding the feasibility and impacts of the proposed "proposed Clean Electricity Regulations", including the 'What We Heard Report' released February 16, 2024. Speci

CYBER SECURITY - Encourage the government to invest in cybersecurity innovation, talent, and infrastructure; modernize research and development; accelerate commercialization in the space; support the secure digitalization of small-and-medium-sized enterprises (SMEs); and improve the global competitiveness of Canada’s cybersecurity industry. ARTIFICIAL INTELLIGENCE - Advocate for future-proofed, globally competitive, and interoperable policies that position artificial intelligence as a positive economic driver, and support the responsible development, deployment, and use of AI in business. PRIVACY AND ACCESS TO INFORMATION - Ensure that the modernization of Canada’s privacy legislation strikes the right balance between protecting consumers and promoting the ability of firms to innovate and compete by responsibly and securely using data. HOUSING - Support policies that enable the creation of more housing supply, incentivize investment in residential construction, and restore housing affordability for Canadian families. NATIONAL SECURITY/ECONOMIC SECURITY - Advancing policies related to enhancing Canada’s economic and national security. Key priorities include strengthening economic resilience, prudently navigating geopolitical challenges to trade and international relations, safeguarding business operations against new and emerging threats, and fostering conditions for economic growth. TRANSPORTATION - Regarding the consistent funding of trade-enabling infrastructure projects; the development of a competitive and efficient transportation network including all modes of transportation. TELECOMMUNICATIONS - Creating the right investment incentives to foster vibrant competition in the sector as a whole; responding to decisions regarding third-party access that will impact the deployment of internet services in rural and remote communities; and responding to regulatory proposals re: cell phone pricing. TAXATION AND FINANCE – With regard to undertaking a comprehensive and independent tax system review. TAXATION AND FINANCE – With regard to the measurement and improvement of Canada’s tax competitiveness, including: reforming the taxation, remittance, filing and audit processes of Canadian businesses; removing tax barriers for childcare expenses; addressing the taxation of family business transfers; and mobilizing private capital for recovery and growth. TAXATION AND FINANCE - With regard to modernizing our financial systems through open banking and digital currencies TAXATION AND FINANCE - Responding to proposals addressing taxation of digital services. TAXATION AND FINANCE - Maintaining and expanding real-time data made freely available to Canadian businesses, municipalities, academic researchers, and community groups. SMALL BUSINESS – Legislation, regulations and support programs that give Canadian small and medium-sized enterprises (SMEs) the tools to grow in Canada and internationally, including reducing their red tape and compliance burden. PRIVACY AND ACCESS TO INFORMATION - Improving digital privacy legislation to meet the needs of industry. PENSIONS - Treatment of corporate pensions in the event of bankruptcy. NATURAL RESOURCES - Support for the adoption of policy recommendations to strengthen Canada’s world-leading position in the mining industry, oil and gas, and forestry products. OPEN DATA - Maintaining and expanding real-time data made freely available to Canadian businesses, municipalities, academic researchers, and community groups. LABOUR: Ensuring that any changes to the Canada Labour Code are implemented in response to defined and demonstrated issues and not to increase regulatory burdens for employers. INTERNATIONAL TRADE – With respect to issues relating to import and export controls INTERNATIONAL TRADE - Negotiating bilateral, regional, and multilateral trade agreements and promoting them to Canadian businesses. INTERNATIONAL TRADE - Improving federal laws and regulations pertaining to responsible business conduct r

Bill S-211, National Framework on Advertising for Sports Betting Act, with respect to gambling advertising regulation in Canada Meetings with federal government will discuss the enactment of legislation to protect Canadians from illegal operators ongoing operations of illegal gambling websites within Canada and to discuss the role of the provincial gaming authorities.

Discussions on the implications of Bill C-265 An Act to amend the Food and Drugs Act (List of Therapeutic Products Pre-approved for Special Access) for patients’ access to drugs for rare diseases. Regulations, guidelines, policies and programs related to regulatory and reporting functions of the Patented Medicine Prices Review Board as they relate to access for patients to rare disease medicines Federally-funded public drug plans, with respect to reimbursement for rare disease medicines for federal plan beneficiaries. Enhancements related to intellectual property legislation, regulations and policies applicable to rare disease medicines. Regulatory amendments and/or guidelines related to the Food and Drugs Act Regulations and Health Canada to implement an orphan drug regulatory framework. Scientific Research and Experimental Development Tax Incentive Program as it pertains to research and development of treatments for rare disorders. Enhancement to Canada's regulatory and funding environment for new rare disease medicines, including Health Canada authorizations of medicines and framework for clinical trials, health technology assessment processes, reimbursement negotiations and funding decisions to improve access for rare disease patients Innovation, Science and Economic Development Canada policies related to research and development for treatments for rare disorders. Implementation of the Pharmacare Act as it relates to rare disease medicines. Implementation of the National Strategy for Drugs for Rare Diseases, and other policies or programs for rare disease medicines.